Cooley Advises Trevena on its Initial Public Offering

New York – February 11, 2014 – Cooley LLP announced today that it advised Trevena, Inc. on its $64.8 million IPO. Trevena is a clinical stage biopharmaceutical company that focuses on the discovery and development of biased ligands to deliver the next generation of GPCR targeted medicines. It now trades on the NASDAQ Global Stock Market under the symbol "TRVN."

Cooley's corporate and securities team advising Trevena included partners Jim Fulton and Brent Siler, as well as associates Derek Colla, Meredith Blount, Kerry Killeen and Robert Lynn. Critical support for the offering was provided by partner Drew Gantt and associate David Sclar (healthcare); partner Susan Cooper Philpot (tax) and partner Natasha Leskovsek (regulatory).

This offering follows Cooley's record year for capital markets work in 2013 in which the firm advised on 60 public offerings, including 23 IPOs, raising more than $8.4 billion. Year-to-date, Cooley has advised on 20 public offerings, including 10 IPOs.

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has more than 750 lawyers across 11 offices in the United States and China.

Related Contacts
Susan Cooper Philpot Retired Partner, San Francisco
Jim Fulton Partner, New York
Brent Siler Partner, Washington, DC
Natasha Leskovsek Partner, Washington, DC
Derek Colla Partner, Washington, DC